Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling.
hronic graft-versus-host disease (GVHD) is a major complication of allogeneic stem-cell transplantation that results in later illness and death and a reduction in quality of life. 1, 2 Risk factors for chronic GVHD are the use of peripheral blood as a source of stem cells, a history of acute GVHD, and the use of donated stem cells with high numbers of T cells. [3] [4] [5] [6] [7] In a meta-analysis, the Stem Cell Trialists' Collaborative Group reported an incidence of extensive chronic GVHD of 47% after peripheral-blood stem-cell transplantation from an HLA-identical sibling. 4 In 2012, more than 70% of the stem-cell transplantations performed in Europe used peripheral blood as a source of stem cells. 6 Although the prevention of acute GVHD has improved in the past two decades, no major improvement has been made in the prevention of chronic GVHD, and randomized studies of therapies aimed at reducing the incidence of chronic GVHD have not been able to achieve their goal. 8, 9 Only antihuman T-lymphocyte immune globulin (ATG) has been shown to lower the incidence of chronic GVHD after stem-cell transplantation from an unrelated donor 10, 11 and, in smaller, retrospective studies, after HLAidentical transplantation. 12, 13 Here we report the results of a trial that was designed to study whether including ATG in the myeloablative conditioning regimen would reduce the risk of chronic GVHD among patients in complete remission from acute leukemia who received peripheralblood stem cells from an HLA-identical sibling.
Me thods

Study Design
In this prospective, multicenter, open-label, phase 3 study, patients were randomly assigned to receive ATG or not receive ATG as part of a myeloablative conditioning regimen. The regimen consisted of cyclophosphamide (120 mg per kilogram of body weight) and total body irradiation (12 Gy) or busulfan (16 mg per kilogram orally or 12.8 mg per kilogram intravenously), with or without etoposide (30 to 60 mg per kilogram), as well as ATG at a dose of 10 mg per kilogram for those randomly assigned to the ATG group, on 3, 2, and 1 days before a transplantation of allogeneic peripheral-blood stem cells from an HLA-identical donor. (For more information on patient disposition see Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.) All siblings were matched serologically for HLA-A and HLA-B and by high-resolution DNA matching for HLA-DRB1 and HLA-DQB1 alleles. Patients were eligible for study participation if they were 18 to 65 years of age, had acute myeloid or lymphoblastic leukemia that was in its first or subsequent complete remission, and had an indication for an allogeneic hematopoietic stem-cell transplantation. Other major criteria for inclusion were adequate function of the major organ systems (hepatic, renal [creatinine clearance of more than 30 ml per minute], pulmonary [diffusing capacity of the lung for carbon monoxide of more than 35%], and cardiac [left ejection fraction of at least 30%]) and the use of stem cells from peripheral blood as the graft source. GVHD prophylaxis consisted of the administration of cyclosporine and a short course of methotrexate (15 mg per square meter of body-surface area on day 1 after transplantation and 10 mg per square meter on days 3, 6, and 11 after transplantation).
Patients were randomly assigned in a 1:1 ratio, with stratification according to center and disease risk. The randomization code was generated by nQuery Advisor, version 6.0, with the use of a permuted, block-randomization plan and a block size of 4. Investigators were unaware of the group assignments until the end of the clinical part of the trial. Each participating center received only complete random blocks.
Study End Points
The primary end point of the study was the cumulative incidence of chronic GVHD at 2 years as determined according to the revised Seattle criteria and the National Institutes of Health (NIH) criteria. 14, 15 Secondary end points included the incidences of engraftment, acute GVHD, nonrelapse-related death, relapse-free and overall survival at 2 years, and a composite end point of chronic GVHD-free and relapse-free survival at 2 years. Acute GVHD was diagnosed according to Glucksberg's criteria, 16 and chronic GVHD according to the modified Seattle criteria (for categorization of chronic GVHD as clinical limited or clinical extensive) 14 (see Tables S2 and S3 , respectively, in the Supplementary Appendix) and according to the NIH criteria for global chronic GVHD scoring (mild, moderate, or severe) and organ involvement (scored as 0, 1, 2 or 3, with higher scores indicating greater involvement). 15 Toxicity in both groups was graded according to the Bearman score. 17 The study started recruitment in October 2006. At the time, there was confusion among European investigators regarding the need to register the trial before initiation of enrollment; the trial was registered in May 2008.
Study Oversight
The study was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. An independent ethics committee at each study site approved the protocol (available at NEJM.org). All patients provided written informed consent. The study was sponsored by the University Medical Center Hamburg-Eppendorf and was conducted in collaboration with the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. The first, second, and last authors designed the study, and Pharmalog (Munich) gathered the data with the use of an electronic case-report form. The third from last author analyzed the data, and that author and the first author vouch for the data and analysis and adherence to the study protocol. The first author wrote the first draft, and all the coauthors made the decision to submit the manuscript for publication. No one who is not an author contributed to the writing of the manuscript. ATG (ATG-Fresenius) was supplied by Neovii Biotech, which also provided additional financial support but did not contribute to the analysis or approve the manuscript for publication.
Statistical Analysis
We used cumulative incidence analysis to assess chronic GVHD-free survival and relapse-free survival and labeled death before the event of interest as a competing risk. 18, 19 Death from relapse was used as a competing risk for the cumulative incidence analysis of death without relapse. Overall survival was assessed with the use of KaplanMeier analysis. Further treatment-group comparisons were performed with the use of chi-square tests for nominal data, Mann-Whitney U-tests for ordinal data, and analyses of variance for interval or ratio-scale data. Exploratory, post hoc, Cox multiple regression analysis was used for subgroup analyses and for the purpose of determining the effect on the incidence of chronic GVHD and on overall survival of recipient age, first versus second remission, acute lymphoblastic versus acute myeloid leukemia, cytogenetic risk, risk of underlying disease, difference between the sex of the donor and the sex of the recipient, cytomegalovirus positivity in the recipient, type of conditioning, CD34+ cells transplanted, grade of acute GVHD and chronic GVHD (time dependent [i.e., the corresponding event can occur at different points in time after transplantation]) in addition to treatment assignment (ATG vs. non-ATG). Confidence intervals for the differences in risk according to treatment group were determined with the use of Wilson's method. 20 The sample size was calculated on the basis of expected 2-year rates of chronic GVHD of 25% in the ATG group and 55% in the non-ATG group. We estimated that a sample size of 160 patients (80 patients in each group) would give the study at least 90% power to reject the null hypothesis in a log-rank test model. All patients who received at least one dose of the conditioning regimen were evaluated for efficacy and safety. Confirmatory testing of the prespecified primary outcome measure, 2-year cumulative incidence of chronic GVHD, was performed in the full analysis set at a type I error level of 0.5 (two-sided). All other P values are considered descriptively (including those that are not significant).
Cumulative incidence analyses were performed with the use of NCSS statistical software, version 9, and R statistical software, version 2.10.1 (cmprsk package). 21, 22 IBM SPSS Statistics software, version 22.0, was used for all other analyses.
R esult s
Patient Characteristics
From December 2006 through February 2012, a total of 168 patients were enrolled at 27 centers; 7 patients were excluded before randomization because they did not meet the inclusion criteria. Of the 161 patients who underwent randomization, 6 were excluded from the analysis because the donor withdrew (2 patients) or progressive disease developed (4 patients). The baseline characteristics of the remaining 155 patients are shown in Table 1 Copyright © 2016 Massachusetts Medical Society. All rights reserved.
T h e ne w e ngl a nd jou r na l o f m e dicine patients undergoing allogeneic stem-cell transplantation (see Table S1 in the Supplementary Appendix), 23 which is determined according to disease status and cytogenetic risk; the number of infused CD34+ cells; and other variables. The only baseline characteristic that differed between the groups was the median age, which was higher in the non-ATG group than the ATG group (43.5 years vs. 39.0 years, P = 0.04). The median dose of cyclosporine at the time of transplantation and at day 100 was 3 mg per kilogram and did not differ significantly between groups (P = 0.63). * A total of 168 patients were enrolled in the study; 7 were excluded before randomization and 6 were withdrawn from the analysis since they did not receive the conditioning regimen or undergo stem-cell transplantation. ATG denotes antihuman T-lymphocyte immune globulin. † The Disease Risk Index includes an assessment of disease type and disease status at the time of transplantation. 
Graft Failure and Engraftment
No graft failure occurred in the ATG group, and one failure occurred in the non-ATG group (1.4% of the patients). The median times to leukocyte engraftment (absolute neutrophil count, ≥0.5×10 9 per liter) and platelet engraftment (platelet count, ≥20×10 9 per liter) were significantly longer in the ATG group than in the non-ATG group: 18 days (range, 10 to 31) versus 15 days (range, 11 to 34) (P<0.001) and 20 days (range, 10 to 110) versus 13 days (range, 6 to 29), respectively (P<0.001) ( Table 2 ).
Acute and Chronic GVHD
The rate of acute GVHD of grade 2, 3, or 4 was 10.8% in the ATG group and 18.1% in the non-ATG group (P = 0.13), and the rate of acute GVHD of grade 3 or 4 was 2.4% in the ATG group and 8.3% in the non-ATG group (P = 0.10) Table 2 ). The median time to the onset of chronic GVHD was 164 days after transplantation in both groups. The cumulative incidence of chronic GVHD at 2 years was 32.2% in the ATG group (95% confidence interval [CI], 22.1 to 46.7) and 68.7% in the non-ATG group (95% CI, 58.4 to 80.7) (P<0.001) (Fig. 1) . The cumulative incidence of minimal or modest chronic GVHD at 2 years, classified as clinical limited chronic GVHD according to the revised Seattle criteria (see Table S3 in the Supplementary Appendix), was 28.1% (95% CI, 18.3 to 43.2) in the ATG group and 53.3% (95% CI, 40.6 to 70.1) in the non-ATG group (P = 0.005; see Fig. S2 in the Supplementary Appendix). The corresponding cumulative incidence of clinical extensive chronic GVHD was 7.6% (95% CI, 3.0 to 19.6) and 52.4% (95% CI, 39.3 to 69.9) (P<0.001) (Fig. 2A) .
The NIH scores for global and organ-specific chronic GVHD were significantly lower in the ATG group than in the non-ATG group (P<0.001); chronic GVHD was classified as mild in 15.6% of the patients in the ATG group versus 16.7% in the non-ATG group, moderate in 8.4% versus 25.0%, and severe in 2.4% versus 22.2% (Table 2) . According to NIH scores, in all organs except genital organs, there was less chronic GVHD involvement of grade 2 or higher in the ATG group than in the non-ATG group, with significantly less involvement of the skin, the mouth, and the eyes (Table 3) . A subgroup analysis of chronic GVHD shows the effect of ATG in subgroups of the full analysis cohort (Fig. S3 in the Supplementary Appendix).
In multivariate analyses, the use of ATG did not result in a significantly greater rate of relapse than the rate without ATG (hazard ratio, 1.03; 95% CI, 0.57 to 1.88; P = 0.91), but the nonsignificant difference in relapse does not justify the conclusion of equivalence. The factors that were associated with the development of chronic GVHD included the presence of previous acute GVHD (hazard ratio, 1.62; 95% CI, 1.29 to 2.05; P<0.001), the combination of female donor and male recipient (hazard ratio, 2.01; 95% CI, 1.11 to 3.65; P = 0.02), and the use of ATG (hazard ratio, 0.37; 95% CI, 0.21 to 0.65; P = 0.001) ( Table  S1 in the Supplementary Appendix).
At 1 year, 91% of the patients in the ATG group who could be evaluated had discontinued cyclosporine, but only 39% in the non-ATG group had done so. Complete resolution of GVHD or the absence of chronic GVHD was reported for 83% of patients in the ATG group versus 63% of patients in the non-ATG group at 6 months, 77% versus 44% at 12 months, and 75% versus 40% at 24 months. Ongoing chronic GVHD was noted in 17% of the patients in the ATG group and in 36% of those in the non-ATG group at 6 months, in 23% and 36%, respectively, at 12 months, and in 25% and 60%, respectively, at 24 months.
Toxicity, Nonrelapse-Related Mortality, and Relapse
Infectious complications were observed in 57.8% of patients in the ATG group and in 54.2% of patients in the non-ATG group (P = 0.65). No post-transplantation lymphoproliferative disorder was observed during follow-up. The rate of cytomegalovirus reactivation was not significantly higher in the ATG group than in the non-ATG group (21.7% and 25.0%, respectively), nor was the rate of Epstein-Barr virus reactivation (3.6% and 1.4%, respectively) or fungal infection (3.6% and 4.2%, respectively) ( Table 2 ). The rate of nonrelapse-related death at 2 years was 14.0% (95% CI, 8.0 to 24.1) in the ATG group and 12.0% (95% CI, 6.1 to 22.4) in the non-ATG group (P = 0.60) (Fig. 2B) . Toxic effects to organs as measured by means of Bearman's score did not differ significantly between groups with the exception of gastrointestinal toxic effects, for which the rate was significantly lower in the ATG group than in the non-ATG group (28.9%
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T h e ne w e ngl a nd jou r na l o f m e dicine vs. 52.8%, P = 0.03) (Tables S5 and S6 in * Where no value is shown, the number of events was too low to calculate a P value. † According to National Health Institutes of Health (NIH) criteria, de novo indicates the onset of chronic GVHD without a history of acute GVHD, quiescent the onset of chronic GVHD after the resolution of acute GVHD, and progressive the onset of chronic GVHD without resolution of acute GVHD. ‡ Chronic, limited, and extensive GVHD are defined according to the Seattle criteria (see Table S3 in the Supplementary Appendix). § Chronic, mild, moderate, and severe GVHD are defined according the NHI criteria (see Table S8 in the Supplementary Appendix). (Fig. 2C ).
Survival
The 2-year rate of relapse-free survival was 59.4% (95% CI, 47.8 to 69.2) in the ATG group and 64.6% (95% CI, 50.9 to 75.3) in the non-ATG group (P = 0.21), and the 2-year rate of overall survival was 74.1% (95% CI, 62.7 to 82.5) and 77.9% (95% CI, 66.1 to 86.1), respectively (P = 0.46) (Fig. 2D and 2E) . In a multivariate analysis, only the diagnosis of acute lymphoblastic leukemia versus acute myeloid leukemia influenced survival (hazard ratio, 2.64; 95% CI, 1.18 to 5.89; P = 0.02), whereas the hazard ratio for survival with ATG versus non-ATG was 0.74 (95% CI, 0.34 to 1.65; P = 0.47) ( Table S4 in the Supplementary Appendix). The rate of the composite end point of 2-year survival free from chronic GVHD and free from relapse was 36.6% (95% CI, 25.2 to 48.0) in the ATG group and 16.8% (95% CI, 9.2 to 26.4) in the non-ATG group (P = 0.005) (Fig. 2F ).
Discussion
Chronic GVHD is the leading cause of late illness and death after allogeneic hematopoietic stem-cell transplantation. 1,2 One of the risk factors for the development of chronic GVHD after allogeneic stem-cell transplantation is the use of peripheral-blood stem cells as a graft source, 4 a factor that may have contributed to the increased incidence of chronic GVHD recently observed by Arai et al., 3 since T-cell levels in grafts are higher than those in the marrow. In our study, the incidence of chronic GVHD at 2 years was 36.5 percentage points lower when ATG was added to the conditioning regimen than when it was not added; the rate of relapse was not significantly higher with ATG, but the nonsignificant difference in relapse rates does not justify the conclusion of equivalence.
More important, the between-group difference in the rate of chronic GVHD was seen mainly in patients with the clinical extensive form of chronic GVHD, with a rate that was 44.8 percentage points lower in the ATG group than in the non-ATG group (7.6% vs. 52.4%), and a lower rate of chronic GVHD involvement was observed in nearly all patients. Within 1 year after transplantation, 91% of patients in the ATG group but only 39% of those in the non-ATG group had discontinued immunosuppressive medication with cyclosporine. The major source of concern associated with any T-cell depletion is the higher risk of relapse that results from the loss of graft-versus-leukemia effects, a result that has been observed in several studies in which in vivo and ex vivo T-cell-depleted grafts were used. 24 After a follow-up of 2 years, we did not observe a significantly higher rate of relapse in the ATG group than in the non-ATG group, with the result that the rates of relapsefree and overall survival were similar in the two groups. Even if a modest increase in the rate of relapse in the ATG group cannot be ruled out, the significantly lower incidence of chronic GVHD with ATG resulted in a significantly higher rate of 2-year survival free from chronic GVHD among patients who received ATG than among those who did not receive ATG (50% vs. 23%). Because the patients in the ATG group were aware of group assignment, the possibility of a certain bias in the grading of chronic GVHD cannot be excluded. The most frequent cause of treatment failure after transplantation is relapse, which in patients with acute leukemia occurs predominantly in the first or second year after transplantation. 25 In the current study, the rate of the composite end point of 2-year survival free from chronic GVHD and free from relapse was significantly higher among those who received ATG than among those who did not (37% vs. 17%).
Chronic GVHD is the second leading cause of death among patients who survive for 2 years after transplantation; extending the follow-up period for these patients would confirm its effect on long-term survival. 1 Unfortunately, our study was terminated at 2 years, and longer-term follow-up data for the patients who participated in this study are not available. We did not observe a higher rate of infectious complications after ATG, as has been reported after the implementation of other T-cell depletion techniques. 10, 11, 26 Although some progress has been made in preventing acute GVHD, most attempts to reduce the risk of chronic GVHD have been unsuccessful. [27] [28] [29] A reduction in the rate of severe acute GVHD and in the rate of chronic GVHD has been observed with ATG only in the case of matched or mismatched, unrelated allogeneic hematopoietic stem-cell transplantation. 10, 11 However, neither of these studies used chronic GVHD as the primary end point.
More recently, post-transplantation cyclophosphamide has been shown in a prospective study to reduce the risk of both acute and chronic GVHD, even after haploidentical stem-cell transplantation, but data from prospective randomized studies are lacking. 30 Other T-cell-depleting strategies (e.g., treatment with alemtuzumab, an anti-CD52 monoclonal antibody, or ex vivo CD34 selection) have been pursued, and low rates of GVHD have been reported. Although such T-celldepleting strategies resulted in a higher risk of relapse among patients with chronic myeloid leukemia, this increased risk does not seem to apply to patients with acute leukemia 31, 32 ; however, concern about an increased risk of relapse associated with the use of T-cell depletion remains.
The ATG preparation used in our study is a polyclonal antihuman T-lymphocyte immune globulin derived from rabbits after immunization with the Jurkat human T-cell line. This highly purified immune globulin consists of antibodies exhibiting a direct effect on T cells through opsonization and lysis after complement activation. Because antigens such as CD19 or CD138 are also targeted by ATG, antitumor effects have been observed in B-cell cancers and to a lesser * According to the National Institutes of Health (NIH) criteria for organ involvement, which rates the extent and severity of chronic GVHD for each organ or site and takes organ function into account, the maximum involvement of the organs listed was ≥2 on a scale of 0 to 3, with 0 indicating no disease, 1 mild disease, 2 moderate disease, and 3 severe disease. 
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T h e ne w e ngl a nd jou r na l o f m e dicine extent in myeloid cancers. 33 Taking into account the effect of donor T cells and B cells on the development of chronic GVHD, [34] [35] [36] the effect of ATG on antigen-presenting cells such as B cells and dendritic cells 37 and the induction of regulatory T cells 38 may have contributed to the significant reduction in chronic GVHD. Other ATGs derived from rabbits or horses have also been used, but because of their different immunologic properties and the lack of reliable comparative studies, the different brands and doses are not interchangeable and the results may not be generalizable to other ATGs.
In summary, our study shows that incorporation of ATG in the myeloablative conditioning regimen before transplantation of peripheralblood stem cells from HLA-identical siblings resulted in a significantly lower rate of chronic GVHD than the rate without ATG. The rates of relapse-free and overall survival were similar in the two groups, but the rate of a composite end point of survival free from chronic GVHD and survival free from relapse was significantly higher with ATG.
